Ral Overactivation in Malignant Peripheral Nerve Sheath Tumors
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Ras leads an important signaling pathway that is deregulated in neurofibromatosis type 1 and malignant peripheral nerve sheath tumor (MPNST). In this study, we show that overactivation of Ras and many of its downstream effectors occurred in only a fraction of MPNST cell lines. RalA, however, was overactivated in all MPNST cells and tumor samples compared to nontransformed Schwann cells. Silencing Ral or inhibiting it with a dominant-negative Ral (Ral S28N) caused a significant reduction in proliferation, invasiveness, and in vivo tumorigenicity of MPNST cells. Silencing Ral also reduced the expression of epithelial mesenchymal transition markers. Expression of the NF1-GTPase-related domain (NF1-GRD) diminished the levels of Ral activation, implicating a role for neurofibromin in regulating RalA activation. NF1-GRD treatment caused a significant decrease in proliferation, invasiveness, and cell cycle progression, but cell death increased. We propose Ral overactivation as a novel cell signaling abnormality in MPNST that leads to important biological outcomes with translational ramifications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brannan, C. I., Perkins, A. S., Vogel, K. S., Ratner, N., Nordlund, M. L., Reid, S. W., Buchberg, A. M., Jenkins, N. A., Parada, L. F., & Copeland, N. G. (1994) · Genes & Development · doi:10.1101/gad.8.9.1019 · Cited by 641
Self-citationA negative feedback signaling network underlies oncogene-induced senescence
Courtois-Cox, S., Genther Williams, S. M., Reczek, E. E., Johnson, B. W., McGillicuddy, L. T., Johannessen, C. M., Hollstein, P. E., MacCollin, M., & Cichowski, K. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.003 · Cited by 501 · cited 1×
“Potential correlation between Ral activation and oncogene-induced senescence (16) is another possibility requiring further study in light of our data that show Ral overactivation in MPNST.”
BackgroundThe exocyst is a Ral effector complex
Moskalenko, S., Henry, D. O., Rosse, C., Mirey, G., Camonis, J. H., & White, M. A. (2002) · Nature Cell Biology · doi:10.1038/ncb728 · Cited by 423 · cited 1×
“RalB directly interacts with the SEC5 subunit of exocyst to facilitate the host defense response (48, 58).”
BackgroundActivation of RalA is critical for Ras-induced tumorigenesis of human cells
Lim, K.-H., Baines, A. T., Fiordalisi, J. J., Shipitsin, M., Feig, L. A., Cox, A. D., Der, C. J., & Counter, C. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.030 · Cited by 355 · cited 3×
“tumor growth in immunodeficient mice (36).”
BackgroundBridging Ral GTPase to Rho Pathways
Jullien-Flores, V., Dorseuil, O., Romero, F., Letourneur, F., Saragosti, S., Berger, R., Tavitian, A., Gacon, G., & Camonis, J. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.38.22473 · Cited by 338
Cantor, S. B., Urano, T., & Feig, L. A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4578 · Cited by 310
The exocyst complex binds the small GTPase RalA to mediate filopodia formation
Sugihara, K., Asano, S., Tanaka, K., Iwamatsu, A., Okawa, K., & Ohta, Y. (2002) · Nature Cell Biology · doi:10.1038/ncb720 · Cited by 258 · cited 1×
“RalB directly interacts with the SEC5 subunit of exocyst to facilitate the host defense response (48, 58).”
BackgroundTurley, E. A., Veiseh, M., Radisky, D. C., & Bissell, M. J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1089 · Cited by 253 · cited 1×
“These include growth factors, receptor tyrosine kinases, Ras and other small GTPases, Src, -catenin, and integrins (5, 63, 64).”
BackgroundRalA and RalB: Antagonistic Relatives in Cancer Cell Migration
Oxford, G., Owens, C. R., Titus, B. J., Foreman, T. L., Herlevsen, M. C., Smith, S. C., & Theodorescu, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1957 · Cited by 139
Ral: Mediator of membrane trafficking
van Dam, E. M., & Robinson, P. J. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.04.006 · Cited by 92
Cited by
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor
Ratner, N., & Miller, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3911 · Cited by 493
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors
Jessen, W. J., Miller, S. J., Jousma, E., Wu, J., Rizvi, T. A., Brundage, M. E., Eaves, D., Widemann, B., Kim, M.-O., Dombi, E., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60578 · Cited by 334
RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer
Yan, C., & Theodorescu, D. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014415 · Cited by 119
“In most models, RALA is the dominant isoform driving tumor progression and metastasis, including in hepatocellular carcinoma (Ezzeldin et al., 2014), malignant peripheral nerve sheath tumors (Bodempudi et al., 2009), and ovarian cancer (Wang et al., 2013).”
BackgroundRal GTPases: crucial mediators of exocytosis and tumourigenesis
Shirakawa, R., & Horiuchi, H. (2015) · Journal of Biochemistry · doi:10.1093/jb/mvv029 · Cited by 76
Ral signaling pathway in health and cancer
Moghadam, A. R., Patrad, E., Tafsiri, E., Peng, W., Fangman, B., Pluard, T. J., Accurso, A., Salacz, M., Shah, K., Ricke, B., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1105 · Cited by 58
Self-citation
Metadata
- Authors
- Bodempudi, V., Yamoutpoor, F., Pan, W., Dudek, A. Z., Esfandyari, T., Piedra, M., Babovick-Vuksanovic, D., Woo, R. A., Mautner, V. F., Kluwe, L., Clapp, D. W., De Vries, G. H., Thomas, S. L., Kurtz, A., Parada, L. F., & Farassati, F.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2009-07-01
- Volume
- 29
- Issue
- 14
- Pages
- 3964-3974
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2128434997
- Cited by
- 51
- References
- 10
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.